Surgery Partners Inc Stock Price, News & Analysis

Surgery Partners, Inc. (NASDAQ:SGRY) reported a net loss of $0.1 million for Q4 2021 and a full-year net loss of $81.2 million. Q4 revenues increased 11.3% to $610.2 million, while full-year revenues rose 19.6% to $2.2 billion. Adjusted EBITDA in Q4 increased 26% to $114.4 million and 32.3% for the year to $339.6 million, aided by CARES Act grants. The company forecasts 2022 revenues to exceed $2.5 billion with Adjusted EBITDA between $370 million and $380 million. Significant investments and capital deployment of $325 million in 2021 underline a strong growth outlook.

Surgery Partners (NASDAQ:SGRY) will announce its fourth quarter 2021 results after market close on February 28, 2022. A conference call will follow at 5:00 p.m. ET to discuss these results. Interested parties can join the call via a domestic phone number (1-877-451-6152) or international number (1-201-389-0879). A replay will be available for a limited time afterward. Surgery Partners, headquartered in Brentwood, TN, operates over 180 locations across 31 states, focusing on outpatient surgical and ancillary care.

Surgery Partners (SGRY) and Privia Health have forged a strategic agreement to enhance healthcare services in Montana. This partnership allows Surgery Partners to utilize Privia's physician enablement capabilities through the Great Falls Clinic, which will anchor Privia's statewide physician network. Additionally, they have established a joint venture to create the Privia Management Company of Montana. This collaboration aims to deliver high-quality surgical care, improve patient experiences, and expand their operational reach across the U.S.

Surgery Partners (NASDAQ: SGRY) reaffirmed its 2021 adjusted EBITDA guidance of $325-$330 million, reflecting a 19%-21% revenue growth over 2020. At the J.P. Morgan Healthcare Conference, the company highlighted recent acquisitions totaling $185 million, with a focus on double-digit EBITDA growth moving into 2022. The leadership transition includes David T. Doherty as CFO, effective February 1, 2022, following Tom Cowhey's departure for new opportunities. The company remains optimistic about its performance amid ongoing pandemic challenges.

Surgery Partners, a top short-stay surgical facility operator, will present at the J.P. Morgan Virtual Healthcare Conference on January 10, 2022, at 5:15 PM (Eastern Time). The event will feature discussions with Wayne S. DeVeydt, Eric Evans, and Tom Cowhey. Interested investors can access the live webcast on the company's website, with replays available afterward. Headquartered in Brentwood, Tennessee, Surgery Partners operates over 180 facilities across 31 states, focusing on high-quality, cost-effective surgical care.

Surgery Partners, Inc. (Nasdaq: SGRY) completed its public offering of 6,900,000 shares at $46.50 per share, raising approximately $320.9 million. The offering included 900,000 shares from the underwriters' option. Proceeds will be used for general corporate purposes, including acquisitions and debt repayment. The offering was conducted under an effective shelf registration statement filed with the SEC. Major bookrunning managers included BofA Securities and J.P. Morgan.

Surgery Partners, Inc. (Nasdaq: SGRY) has priced its public offering of 6,000,000 shares at $46.50 each, aiming to raise approximately $279 million. The offering, closing on or about November 12, 2021, includes a 30-day option for underwriters to purchase an additional 900,000 shares. Proceeds will support general corporate purposes, including acquisitions and debt repayment. BofA Securities, J.P. Morgan, and Jefferies are leading the offering.

Surgery Partners announced a public offering of 5,000,000 shares of its common stock, with an option for underwriters to purchase an additional 750,000 shares. The offering is subject to market conditions and the actual size may vary. Proceeds will be used for general corporate purposes. The shares are offered under an effective shelf registration statement filed with the SEC on January 25, 2021. BofA Securities, J.P. Morgan, and Jefferies are the lead managers for the offering.

Surgery Partners (NASDAQ:SGRY) reported strong Q3 2021 results, with revenues of $559.2 million, a 12.7% increase year-over-year. Adjusted EBITDA rose 25% to $76.4 million. Despite a net loss of $22.9 million, the company anticipates FY 2021 adjusted EBITDA of $325-$330 million. Key drivers included a 6.2% increase in same-facility case volume and a strategic focus on high-acuity procedures. Cash and equivalents stood at $330.4 million. Overall, Surgery Partners is well-positioned for growth amid the ongoing pandemic.